RETI

RetiSpec is a medical technology company that develops AI-driven diagnostic tools for the early detection of neurodegenerative diseases through a simple eye exam. The company's proprietary hyperspectral imaging technology identifies the unique optical signature of amyloid beta biomarkers in the retina, which are indicative of Alzheimer's disease. By providing a non-invasive, cost-effective, and rapid screening method, RetiSpec aims to enable earlier intervention and improve patient outcomes in the management of cognitive decline. Their solution is designed to be integrated into routine clinical workflows, such as those in optometry and ophthalmology clinics.